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Abstract TRF2 is a ubiquitous protein that protects telomeres
in the nucleus. We found that TRF2 was present at the periph-
eral nerve axons and the brain neuroglial cell processes exten-
sively. It was in the cytoplasmic membrane as well as nuclear
fractions, but not in the soluble cytoplasmic fraction of SH-
SY5Y neuroblastoma cells. TRF2 was up-regulated in P19 em-
bryonal carcinoma cells at the early stage of induced neural
di¡erentiation with retinoic acid treatment. Upon transfection,
TRF2-expressing COS cells often produced neurite-like long
cytoplasmic processes. TRF2 is a component of neuroglial cells
and appears to be involved in the cytoplasmic process formation
that is necessary for neural di¡erentiation.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
TRF2 (TTAGGG repeat binding factor 2) is a nuclear pro-
tein that coats the length of all human telomeres at all stages
of the cell cycle [1,2]. It protects telomeres from end-to-end
fusion [3] by forming large duplex loops at the end [4]. It
delays replicative senescence of cultured cells by protecting
critically short telomeres from fusion [5].
TRF2 inhibition leads to immediate induction of apoptosis
suggesting that TRF2-depleted telomeres are perceived as if
they represent sites of DNA damage [6]. TRF2 binds with
several telomere-regulating proteins such as hRap1 [7],
Mre11 complex [8], Ku [9], and Werner and Bloom syndrome
helicases [10], suggesting that it protects and maintains the
telomere function in collaboration with other proteins. The
down-regulation of TRF2 has been implicated in malignancies
[11,12].
We have screened the expression of TRF2 in various tissues
using a⁄nity-puri¢ed anti-TRF2 antibody [9]. Upon immuno-
histochemical staining, we unexpectedly found that TRF2 was
present not only in the nuclei but also at the axon of periph-
eral nerves and brain tissue. Here, we show that TRF2 is a
neuroglial cell component and induces neurite-like cytoplas-
mic process formation. Our results suggest that TRF2 has a
novel function of neurite formation that is not related to the
telomere-protecting function.
2. Materials and methods
2.1. Immunohistochemistry
Para⁄n-embedded and/or fresh human tissue samples from various
organs were obtained from autopsy and surgical pathology ¢les at
Asan Medical Center, Seoul, Korea, with informed written consent.
For the immunohistochemical staining, sections of 4 Wm thickness
were prepared from para⁄n blocks. Microwave antigen retrieval
was applied in 0.01 M sodium citrate bu¡er (pH 6.0). The a⁄nity-
puri¢ed anti-TRF2 antibody was produced against recombinant
TRF2 expressed in Escherichia coli [9]. For negative control, antigen
pre-absorbed antibody was applied. Anti-TuJ1 (Covance, Richmond,
CA, USA), anti-NeuN (Chemicon, Temecula, CA, USA), anti-synap-
tophysin (DakoCytomation, Carpinteria, CA, USA), and anti-neuro-
¢lament (DakoCytomation) antibodies were applied for 2 h at room
temperature similarly. After washing, immunostaining was done using
the avidin-biotinylated horseradish peroxidase complex method, and
was developed by immersing slides in diaminobenzidine as chromo-
gen.
2.2. Tissue culture and induced neural di¡erentiation
SH-SY5Y [13] and COS cells were grown at 37‡C (5% CO2) in
Dulbecco’s modi¢ed Eagle’s medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% (v/v) fetal bovine serum, penicillin
(100 IU/ml), and streptomycin (100 mg/ml). P19 cells obtained from
the American Type Culture Collection (Rockville, MD, USA) [14]
were cultured in K-minimal essential medium (Invitrogen) supple-
mented with 7.5% fetal bovine serum and 2.5% fetal calf serum (In-
vitrogen). To induce neuronal di¡erentiation, SH-SY5Y cells were
incubated in complete medium plus 1 WM all-trans retinoic acid (Sig-
ma, St. Louis, MO, USA) for 5 days [15].
P19 cells were grown in 100 mm bacteriological grade Petri dishes.
To induce neural di¡erentiation, all-trans retinoic acid was added to
the medium to a ¢nal concentration of 0.5 WM [16]. After 4 days, the
cell aggregates were trypsinized, transferred into tissue culture dishes
and cultured for an additional 5 days in the same medium without
retinoic acid. Cells were harvested every 24 h and analyzed by West-
ern blot for 5 days.
2.3. Cell fractionation
Cell fractionation experiments were repeated twice independently.
SH-SY5Y cells were washed with cold phosphate-bu¡ered saline
(PBS), scraped from the plates and allowed to swell in 0.5 ml of lysis
bu¡er (50 mM Tris^HCl (pH 7.4), 2 mM EDTA, 2 mM EGTA, 1 mM
dithiothreitol, 10 Wg/ml leupeptin, 10 Wg/ml aprotinin, 10 Wg/ml tryp-
sin inhibitor, 1 mM phenylmethylsulfonyl £uoride, 1 mM NaF, 1 mM
sodium orthovanadate, 0.1% (v/v) Triton X-100) on ice for 10 min.
Then, cells were homogenized with 10 gentle strokes of a glass-to-glass
Dounce homogenizer. The homogenates were ¢rst centrifuged (at
600Ug and 4‡C for 20 min) to obtain a crude nuclear pellet and a
soluble fraction. The purity of the nuclear preparations was moni-
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tored routinely by phase contrast microscopy after staining with
methylene blue. The soluble fraction was further centrifuged (at
100 000Ug and 4‡C for 30 min) to yield a cytoplasmic soluble super-
natant and a plasma membrane pellet. The crude nuclear pellet was
washed with the lysis bu¡er, layered over 45% (w/v) sucrose, centri-
fuged (at 1660Ug and 4‡C for 30 min), resuspended and sonicated in
the lysis bu¡er containing 1% (v/v) Triton X-100. Then, the homog-
enate was centrifuged (at 14 000Ug and 4‡C for 30 min) to yield
soluble and insoluble nuclear fractions.
2.4. Western blot
SH-SY5Y cell fractions, retinoic acid-treated P19 cells, or tissue
samples were solubilized in the lysis bu¡er. Protein concentrations
were measured by the Bradford method (Bio-Rad Laboratories, Her-
cules, CA, USA), and the same amount of total proteins was loaded
in each lane. After 10% sodium dodecyl sulfate^polyacrylamide gel
electrophoresis, the separated peptides were transferred to nitrocellu-
lose paper. A⁄nity-puri¢ed anti-TRF2 antibody and anti-TuJ1 anti-
bodies were used as primary antibodies. For the control, anti-L-actin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibody was
used similarly. Immune complexes were visualized using the enhanced
chemiluminescence detection system (Amersham, Buckinghamshire,
UK). The intensities of bands were determined densitometrically using
a Multi-Image Analysis System (Bio-Rad Laboratories). Data were
expressed as arbitrary densitometric values normalized against L-actin
in fold increase of control.
2.5. Transfection and immuno£uorescence microscopy
COS cells grown on coverslips were transfected using pcDNA3-
TRF2/T7WTag or pcDNA3-TRF2vBvM/T7WTag, a mutant deleted in
the N-terminus and the myb-like C-terminus [9]. Cells were trans-
fected with 3 Wg of plasmid DNA/60 mm dish using LipofectAMINE
PLUS1 reagent (Invitrogen). Three experiments were performed in-
dependently. For a negative control, cells were transfected with the
vector alone. At 36 h after transfection, cells were ¢xed in cold meth-
anol at 320‡C, and processed for immuno£uorescence microscopy.
A⁄nity-puri¢ed anti-TRF2 antibody and/or monoclonal anti-T7Wtag
antibody (Novagen, Madison, WI, USA) were applied as primary
antibodies. As controls, normal rabbit and/or mouse sera were used.
Rhodamine-conjugated anti-rabbit IgG secondary antibody and/or
£uorescein isothiocyanate-conjugated anti-mouse IgG secondary anti-
body (Zymed, South San Francisco, CA, USA) were applied as
second antibodies for 30 min. After washing with PBS three times,
nuclei were stained with 4P,6-diamidino-2-phenylindole (Sigma) and
mounted. Cells were viewed using an Olympus Vanox-S £uorescence
microscope.
3. Results and discussion
3.1. TRF2 is present at the peripheral nerve axons and brain
neuroglial cell processes
To understand the TRF2 function further, we surveyed the
expression in human tissues by immunohistochemistry using
a⁄nity-puri¢ed rabbit antisera [9]. In every organ, most cells
were immunostained in the nuclei, although the staining in-
tensity varied considerably. Unexpectedly, we found that pe-
ripheral nerve axons were strongly immunostained regardless
of the size or location (Fig. 1A). Similarly, the brain was also
extensively immunostained while antigen pre-absorbed control
antibodies did not show any staining. All neurons had intense
TRF2 immunostaining throughout the soma and processes
displaying the complex neural network of the brain (Fig.
1B). There was also a ¢nely ¢brillar staining in the white
matter, where no neuron expressing synaptophysin was
present, indicating that TRF2 was also present in the glial
processes (Fig. 1C,D). The distribution of TRF2 in the central
nervous system was reminiscent of TuJ1 (neuron-speci¢c class
III L-tubulin) [17] except that nuclei were negative on TuJ1
immunostaining (Fig. 1E). NeuN was expressed in the neuro-
nal nuclei and soma similarly [18], but it was not expressed in
glial cells (Fig. 1F). Neuroblastomas and gliomas, which are
malignant neural and glial tumors, also strongly expressed
TRF2 at the neural and glial processes, respectively (Fig.
1G,H).
As reported previously, TRF2 was detected as two bands of
65 and 69 kDa upon Western blotting [1,2]. The expression of
TRF2 varied considerably in di¡erent organs: it was much
higher in the brain than in organs such as thymus, kidney,
lung and liver (Fig. 2A). L-Actin, which was taken as a con-
trol, was also highly expressed in the brain. From the densi-
tometric analysis of immunoblots, the TRF2 expression nor-
malized against L-actin was still higher in the brain than in
other organs (Fig. 2B).
3.2. TRF2 is in the nuclear and cytoplasmic membrane
fractions but not in the soluble cytoplasmic fraction of
neuroblastoma cells
We then analyzed in which cellular fraction TRF2 was
present. SH-SY5Y neuroblastoma cells were treated with
Fig. 1. TRF2 is a component of the peripheral and central nervous
system. A: Immunohistochemical staining of peripheral nerve show-
ing intense staining of TRF2 at the axons (brown color). B: Brain
neurons also express TRF2 in the soma and neurites extensively. C:
TRF2-positive network in both gray matter (upper part) and white
matter (lower part) of the brain. D: In the step section of C, the
boundary of gray matter is shown by expression of synaptophysin,
a neural marker. E: TuJ1 immunostaining of neuronal soma and
processes, but nuclei are negative. F: NeuN immunostaining in
both neuronal nuclei and cytoplasm. G: Neoplastic neural cells in
neuroblastoma also express TRF2 in the soma, neurites and nuclei.
H: Neoplastic glial cells in a glioma also express TRF2 in the deli-
cate glial processes. (A,B,E^H: U100; C,D: U50). (For interpreta-
tion of the references to color in this ¢gure legend, the reader is re-
ferred to the web version of this article.)
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1 WM retinoic acid to induce neural di¡erentiation [15]. Cells
were harvested after 5 days when more than 90% of cells
showed TuJ1-positive neurites, and cellular fractions were pre-
pared as described in Section 2. Upon 10% polyacrylamide gel
electrophoresis and immunoblotting, TRF2 was detected in
the cytoplasmic membrane fraction as well as in the soluble
and insoluble nuclear fractions, but not in the soluble cyto-
plasmic fraction (Fig. 3). TRF2 consisted of two bands with
similar proportions in each fraction. From the densitometric
analysis, it was estimated that the amount of TRF2 in the
cytoplasmic membrane fraction was about 45% of the total
TRF2 in the di¡erentiated SH-SY5Y cells.
3.3. TRF2 is up-regulated at the early stage of induced neural
di¡erentiation of P19 cells
The abundance of TRF2 in the cytoplasmic membrane frac-
tion suggested a particular function in the nervous system,
distinct from the telomere regulation. We checked the expres-
sion of TRF2 during the experimental neural di¡erentiation.
For the experiment, we used P19 embryonal carcinoma cells
instead of SH-SY5Y cells, because the former did not show
any visible ‘leakage’ of neurite formation in the culture con-
ditions without retinoic acid. After the exposure to 0.5 WM
retinoic acid for 4 days, P19 cells were replated in tissue cul-
ture £asks. On immunoblotting, TuJ1 began to be detected
48 h post treatment and increased exponentially afterwards,
indicating the induction and ongoing neural di¡erentiation
(Fig. 4A,B). TRF2 also increased after the retinoic acid treat-
ment, but in a distinct pattern from TuJ1: the TRF2 expres-
sion normalized against L-actin increased up to 2.19 times of
the basal level on the third day, and began to decrease after-
wards (Fig. 4A,C). The expression of L-actin did not change
signi¢cantly for 5 days. The TRF2 up-regulation before TuJ1
induction suggested that TRF2 might have a direct role in the
induction of neurites at the early stage of neural di¡erentia-
tion.
Fig. 2. Western blot for TRF2 in human tissues. A: Upon loading
of 30 Wg of total proteins in each lane, the TRF2 expression is
much higher in the brain than in other tissues. The control L-actin
is also highly expressed in the brain. B: From the densitometric
analysis of immunoblots, the TRF2 expression normalized against
L-actin was still higher in the brain than in other organs.
Fig. 3. TRF2 is present in the nuclear and cytoplasmic membrane
fractions but not in the cytoplasmic soluble fraction of neuroblasto-
ma cells. SH-SY5Y cells were induced to undergo neural di¡erentia-
tion using 1 WM retinoic acid, and cellular fractions were prepared
as described. TRF2 was detected as two bands of 65 and 69 kDa
with similar proportions among the fractions. Total protein 20 Wg
was loaded in each lane: 1, soluble nuclear fraction; 2, insoluble
nuclear fraction; 3, soluble cytoplasmic fraction; and 4, cytoplasmic
membrane fraction.
Fig. 4. TRF2 up-regulation at the early stage of induced neural dif-
ferentiation. A: Immunoblot using anti-TuJ1, TRF2, and L-actin
antibodies. P19 embryonal carcinoma cells were treated with 0.5
WM retinoic acid and harvested every 24 h. Lane 1: untreated con-
trol, lanes 2^6: days 1^5 after treatment. Total protein 20 Wg was
loaded in each lane. B: The expression of TuJ1 normalized against
L-actin expression as a control. C: The normalized expression of
TRF2.
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3.4. TRF2 transfection induces neurite-like processes in COS
cells
We then examined whether TRF2 could induce neurite-like
processes in cultured cells. COS cells were transfected with
either pcDNA3-TRF2/T7WTag or pcDNA3-TRF2vBvM/
T7WTag, a mutant deleted in the N-terminus and the myb-
like C-terminus [9]. For negative control, cells were trans-
fected with the vector alone. At 36 h post transfection, cells
were processed for immuno£uorescence microscopy using
anti-TRF2 and/or anti-T7WTag antibodies. The transfection
e⁄ciency varied from 3 to 10% among three repetitions.
Transfected COS cells showed strong immunostaining in the
nuclei and/or cytoplasm. Among the TRF2-transfected COS
cells, about 10^20% had slender cytoplasmic processes, which
were not present in the mock transfection. They had two or
more processes that were up to 20^30 times of the nuclear
length (Fig. 5A,B): the nuclei were small and slender in com-
parison with other cells. Transfected cells had either bipolar
or multipolar processes. The processes were quite reminiscent
of neurites: they often showed a beaded appearance, branched
and connected to adjacent cell processes. However, they did
not express neural markers such as TuJ1, NeuN, neuro¢la-
ment, or synaptophysin on double immunostaining (data not
shown). The neurite-like processes were found on both full-
length TRF2 and TRF2vBvM transfection, indicating that nei-
ther the N- nor the C-terminus was involved in the neurite-
like process formation.
Taken together, TRF2 is present abundantly in the cyto-
plasmic membrane fraction of neural cells, and appears to
induce the neurite-like cytoplasmic processes. Our data sug-
gest that the neurite formation may precede further biochem-
ical steps toward mature neurons. The molecular mechanisms
of neural process initiation and growth have not been well
elucidated. It has been shown that Rho-GTPases and Cdc42
are involved in the axon initiation and growth [19], and the
regulation of actin polymerization through the Arp2/3 com-
plex [20]. Given that TRF2 induces neurite-like processes in
non-neural cells, it is likely that TRF2 functions upstream of
those pathways in the complex molecular mechanism of neu-
ral di¡erentiation.
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Fig. 5. COS cells transfected with TRF2 produce neurite-like pro-
cesses. A,B: Immuno£uorescence microscopy of COS cells harvested
36 h after transfection using monoclonal anti-T7WTag and rabbit
anti-TRF2 antibodies, respectively (U50 and U100). Transfected
cells often display neurite-like processes with strong immuno£uores-
cence staining for TRF2. The long and slender processes are often
branching and connected to other cells. Nuclei are designated
with arrows. Both pcDNA3-TRF2/T7WTag or pcDNA3-TRF2vBvM/
T7WTag, a mutant deleted in the N-terminus and the myb-like C-ter-
minus, show similar results.
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